Jiahao Su^*, Meiqin Cai^*, Wensheng Li^*, Bo Hou^†, Haiyong He^†, Cong Ling^†,Tengchao Huang^†, Huijiao Liu^†, Ying Guo^*

Oncology Research, Vol.24, No.2, pp. 117-128, 2016, DOI:10.3727/096504016X14612603423511

Abstract Glioblastoma (GBM) is the most common primary malignant brain tumor that nearly always results in a bad prognosis. Temozolomide plus radiotherapy (TEM+RAD) is the most common treatment for newly diagnosed GBM. With the development of molecularly targeted drugs, several clinical trials were reported; however, the efficacy of the treatment remains controversial. So we attempted to measure the dose of the molecularly targeted drug that could improve the prognosis of those patients. The appropriate electronic databases (PubMed, MEDLINE, EMBASE, and the Cochrane Library) were searched for relevant studies. A meta-analysis was performed after determining which studies… More >

Roberta Milani^*, Eleonora Brognara^*, Enrica Fabbri^*, Alessia Finotti^*, Monica Borgatti^*, Ilaria Lampronti^*, Giovanni Marzaro^†, Adriana Chilin^†, Kenneth Ka-Ho Lee^‡, Stanton Hon-Lung Kok^‡, Chung-Hin Chui^§, Roberto Gambari^*

Oncology Research, Vol.26, No.9, pp. 1307-1315, 2018, DOI:10.3727/096504017X14928634401187

Abstract Glioblastoma multiforme (GBM), a malignant tumor of the central nervous system, has a high mortality rate. No curative treatment is presently available, and the most commonly used chemotherapeutic drug, the alkylating agent temozolomide (TMZ), is only able to increase life expectancy and is often associated with drug resistance. Therefore, an urgent need does exist for novel drugs aimed at treating gliomas. In the present study, we obtained three major results using corilagin: (a) demonstrated that it inhibits the growth of U251 glioma cells through activation of the apoptotic pathway; (b) demonstrated that it is also More >

TAO LI^#, XIN FU^#, JIE WANG, WEI SHANG, XIAOTONG WANG, LINYUN ZHANG, JUN LI^*

Oncology Research, Vol.31, No.3, pp. 345-359, 2023, DOI:10.32604/or.2023.028724

Abstract Temozolomide (TMZ) resistance is a major obstacle in glioma treatment. Nuclear protein-1 (NUPR1) is a regulator of glioma progression. This study investigated the mechanism of NUPR1 in TMZ resistance in hypoxia-treated glioma cells and its mechanism in modulating autophagy. We treated TMZ-resistant cells U251-TMZ and T98G-TMZ to normoxia or hypoxia and silenced NUPR1 in hypoxia-treated U251-TMZ and T98G-TMZ cells to assess cell viability, proliferation, apoptosis, LC3-II/LC3-I and p62 expressions, and autophagic flux under different concentrations of TMZ. We found that hypoxia upregulated NUPR1 expression and autophagy while NUPR1 silencing suppressed hypoxia-induced TMZ resistance and autophagy… More > Graphic Abstract

Jia Liu^*, Ying Zhang^†, Shulan Sun^‡, Guirong Zhang^‡, Ke Jiang,§ Peixin Sun^*, Ye Zhang^*, Bing Yao^*, Rui Sui^*, Yi Chen^*, Xu Guo^*, Tao Tang^*, Ji Shi^*, Haiyang Liang^*, Haozhe Piao^*

Oncology Research, Vol.27, No.4, pp. 475-486, 2019, DOI:10.3727/096504018X15270916676926

Abstract Glioma is the most common malignant tumor of the central nervous system, and it is characterized by high relapse and fatality rates and poor prognosis. Bufalin is one of the main ingredients of Chan-su, a traditional Chinese medicine (TCM) extracted from toad venom. Previous studies revealed that bufalin exerted inhibitory effects on a variety of tumor cells. To demonstrate the inhibitory effect of bufalin on glioma cells and glioma stem-like cells (GSCs) and discuss the underlying mechanism, the proliferation of glioma cells was detected by MTT and colony formation assays following treatment with bufalin. In… More >

Rosa Della Monica^*1, Mariella Cuomo^*†1, Roberta Visconti^‡, Annabella di Mauro^§, Michela Buonaiuto^*, Davide Costabile^*†, Giulia De Riso^†, Teodolinda Di Risi^*, Elia Guadagno^¶, Roberto Tafuto^#, Sabrina Lamia^**, Alessandro Ottaiano^††, Paolo Cappabianca^#, Maria Laura Del Basso de Caro^¶, Fabiana Tatangelo^§, Juergen Hench^‡‡, Stephan Frank^‡‡, Salvatore Tafuto^**, Lorenzo Chiariotti^*†

Oncology Research, Vol.28, No.9, pp. 837-845, 2020, DOI:10.3727/096504021X16214197880808

Abstract Unresectable neuroendocrine neoplasms (NENs) often poorly respond to standard therapeutic approaches. Alkylating agents, in particular temozolomide, commonly used to treat high-grade brain tumors including glioblastomas, have recently been tested in advanced or metastatic NENs, where they showed promising response rates. In glioblastomas, prediction of response to temozolomide is based on the assessment of the methylation status of the MGMT gene, as its product, O6 -methylguanine-DNA methyltransferase, may counteract the damaging effects of the alkylating agent. However, in NENs, such a biomarker has not been validated yet. Thus, we have investigated MGMT methylation in 42 NENs of… More >